SCYNEXIS, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- SCYNEXIS, Inc. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $14.20M.
- SCYNEXIS, Inc. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $11.43M.
- SCYNEXIS, Inc. stock issued during period, value, new issues for the quarter ending 2025-12-31 was $1.00K.
- SCYNEXIS, Inc. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $3.00K.
- SCYNEXIS, Inc. stock issued during period, value, new issues for fiscal 2025 was $4.00K.
- SCYNEXIS, Inc. stock issued during period, value, new issues for fiscal 2023 was $4.00K, a 99.98% decline from fiscal 2022.
- SCYNEXIS, Inc. stock issued during period, value, new issues for fiscal 2022 was $21.01M, a 48.81% decline from fiscal 2021.
- SCYNEXIS, Inc. stock issued during period, value, new issues for fiscal 2021 was $41.04M, a 28.23% decline from fiscal 2020.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $14.20M 10-Q · filed 2026-08-10 | $25.63M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $11.43M 10-Q · filed 2026-05-11 | |
| 2025-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $4.00K 10-K · filed 2026-03-04 |
| 2025-09-30 | $3.00K 10-Q · filed 2025-11-05 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $4.00K 10-K · filed 2025-03-12 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $4.00K derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $4.00K 10-Q · filed 2024-08-08 | $99.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-08 | $18.89M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $21.01M 10-K · filed 2024-03-28 |
| 2022-09-30 | $95.00K 10-Q · filed 2023-11-13 | $53.35M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $18.80M 10-Q · filed 2023-08-14 | $58.56M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $2.13M 10-Q · filed 2023-05-10 | $43.18M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $32.33M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $41.04M 10-K · filed 2023-03-31 |
| 2021-09-30 | $5.30M 10-Q · filed 2022-11-09 | $61.32M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $3.42M 10-Q · filed 2022-08-15 | $57.93M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-17 | $56.98M derived: sum of 4 quarters · filed 2022-03-29 |
| 2020-12-31 | $52.61M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $57.18M 10-K · filed 2022-03-29 |
| 2020-09-30 | $1.91M 10-Q · filed 2021-11-10 | $25.35M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $2.46M 10-Q · filed 2021-08-16 | $26.64M derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | $207.00K 10-Q · filed 2021-05-17 | $28.23M derived: sum of 4 quarters · filed 2021-05-17 |
| 2019-12-31 | $20.77M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $30.53M 10-K · filed 2021-03-29 |
| 2019-09-30 | $3.21M 10-Q · filed 2020-11-06 | $10.70M derived: sum of 4 quarters · filed 2020-11-06 |
| 2019-06-30 | $4.05M 10-Q · filed 2020-08-10 | $7.99M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | $2.51M 10-Q · filed 2020-05-11 | $3.95M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | $939.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $20.44M 10-K · filed 2020-03-11 |
| 2018-09-30 | $498.00K 10-Q · filed 2019-11-12 | $20.81M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $23.90M derived: sum of 4 quarters · filed 2019-08-07 |
| 2018-03-31 | $19.00M 10-Q · filed 2019-05-08 | $25.78M derived: sum of 4 quarters · filed 2019-05-08 |
| 2017-12-31 | $1.32M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $9.95M 10-K · filed 2019-03-14 |
| 2017-09-30 | $3.58M 10-Q · filed 2018-11-13 | $13.43M derived: sum of 4 quarters · filed 2018-11-13 |
| 2017-06-30 | $1.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | |
| 2017-03-31 | $3.17M 10-Q · filed 2017-05-08 | |
| 2016-12-31 | $4.79M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13 | $21.39M 10-K · filed 2018-03-13 |
| 2015-12-31 | $38.01M 10-K · filed 2017-03-13 | |
| 2014-12-31 | $54.58M 10-K · filed 2017-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |